CoChat
Sign Up
Cited by 67

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Glycoprotein 330/Megalin (LRP-2) Has Low Prevalence as mRNA and Protein in Brain Microvessels and Choroid Plexus

Chun, Jong T., Wang, Liang, Pasinetti, Giulio M., Finch, Caleb E., Zlokovic, Berislav V.·1999·Experimental Neurology
DOI 10.1006/exnr.1999.7052
Open this paper in CoChat — free account

Abstract

Prior studies indicated that glycoprotein 330 (gp330)/megalin mediates transcytosis of apolipoprotein J (apoJ) with Alzheimer's amyloide-peptide (Abeta) across the vascular membranes of the central nervous system (CNS). Here we show the presence of gp330/megalin mRNA and gp330-like immunoepitopes in brain capillaries and choroid plexus and their absence from brain parenchyma. By polymerase chain reaction (PCR) we estimated 1.2 x 10(5) molecules (1 pg) of gp330/megalin mRNA/microg total brain capillary RNA, which is 3% of that in kidney RNA. However, gp330 mRNA was not detected by in situ hybridization in vascular CNS tissue, presumably because of low transcript prevalence. The ratio of gp330 protein:RNA was 17-fold higher in choroid plexus vs brain capillaries, which implies tissue specific regulation of the protein and mRNA prevalence. We conclude that gp330/megalin mRNA and protein are expressed in brain capillaries and choroid plexus in small amounts that are consistent with the observed activities of this endocytosing receptor in the regulation of apoJ and Abeta uptake by the CNS.

Overview

Integrity signals

Registry

Crossref · 10.1006/exnr.1999.7052

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 39

  1. Abbate, 1993, Location of gp330/alpha 2-m receptor-associated protein (alpha 2-MRAP) and its binding sites in kidney: Distribution of endogenous α2-MRAP is modified by tissue processing, Eur. J. Cell Biol., 61, 139
  2. Brown, 1997, LDL-receptor structure: Calcium cages, acid baths and recycling receptors, Nature, 388, 629, 10.1038/41672 · DOI · Paper page
  3. Christie, 1996, Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system and in Alzheimer's disease, J. Neuropathol. Exp. Neurol., 55, 491, 10.1097/00005072-199604000-00012 · DOI · Paper page
  4. Dehouck, 1997, A new function for the LDL receptor: Transcytosis of LDL across the blood–brain barrier, J. Cell Biol., 138, 877, 10.1083/jcb.138.4.877 · DOI · Paper page
  5. Farquhar, 1995, The unfolding story of megalin (gp330): Now recognized as a drug receptor, J. Clin. Invest., 96, 1184, 10.1172/JCI118149 · DOI
  6. Farquhar, 1995, The Heymann nephritis antigenic complex: Megalin (gp330) and RAP, J. Am. Soc. Nephrol., 6, 35, 10.1681/ASN.V6135 · DOI
  7. Galau, 1977, Significance of rare mRNA sequences in liver, Arch. Biochem. Biophys., 179, 584, 10.1016/0003-9861(77)90147-3 · DOI
  8. Hammad, 1997, Interaction of apolipoproteinJ, J. Biol. Chem., 272, 18644, 10.1074/jbc.272.30.18644 · DOI
  9. Jenne, 1992, Clusterin: The intriguing guises of a widely expressed glycoprotein, Trends Biochem. Sci., 17, 154, 10.1016/0968-0004(92)90325-4 · DOI
  10. Joiken, 1994, Regulation of the very low density lipoprotein receptor by thyroid hormone in rat skeletal muscle, J. Biol. Chem., 269, 26411, 10.1016/S0021-9258(18)47209-2 · DOI
  11. Kerjaschki, 1983, Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats, J. Exp. Med., 157, 667, 10.1084/jem.157.2.667 · DOI
  12. Kerjaschki, 1987, Identification of a 400-kd protein in the brush borders of human kidney tubules that is similar to gp330, the nephritogenic antigen of rat Heymann nephritis, Am. J. Pathol., 129, 183
  13. Kerjaschki, 1987, Initial events in the formation of immune deposits in passive Heymann nephritis: gp330-Anti-gp330 immune complexes form in epithelial coated pits and rapidly become attached to the glomerular basement membrane, J. Exp. Med., 166, 109, 10.1084/jem.166.1.109 · DOI
  14. Kounnas, 1993, Glycoprotein 330, a member of the low density lipoprotein receptor family, binds lipoprotein lipasein vitro, J. Biol. Chem., 268, 14176, 10.1016/S0021-9258(19)85224-9 · DOI
  15. Kounnas, 1994, Immunological localization of glycoprotein 330, low density lipoprotein receptor related protein and 39-kDa receptor associated protein in embryonic mouse tissues, In Vivo, 8, 343
  16. Kounnas, 1995, Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin, J. Biol. Chem., 270, 13070, 10.1074/jbc.270.22.13070 · DOI
  17. LaFerla, 1997, Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Aβ stabilization, J. Clin. Invest., 100, 310, 10.1172/JCI119536 · DOI
  18. Matsuo, 1987, Glomerulonephritis induced in the rabbit by antiendothelial antibodies, J. Clin. Invest., 79, 1798, 10.1172/JCI113021 · DOI
  19. Moestrup, 1995, Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs, J. Clin. Invest., 96, 1404, 10.1172/JCI118176 · DOI
  20. Nudel, 1983, The nucleotide sequence of the rat cytoplasmic beta-actin gene, Nucleic Acids Res., 11, 1759, 10.1093/nar/11.6.1759 · DOI
  21. Orlando, 1993, Identification of a cell line that expresses a cell surface and a soluble form of the gp330/receptor-associated protein (RAP) Heymann nephritis antigenic complex, Proc. Natl. Acad. Sci. USA, 90, 4082, 10.1073/pnas.90.9.4082 · DOI
  22. Page, 1998, Dissociation of apolipoprotein and apolipoprotein receptor response to lesion in the rat brain. An in situ hybridization study, Neuroscience, 58, 1161, 10.1016/S0306-4522(97)00661-1 · DOI
  23. Pasinetti, 1994, Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain, J. Comp. Neurol., 339, 387, 10.1002/cne.903390307 · DOI
  24. Poirier, 1994, Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease, Trends Neurosci., 17, 525, 10.1016/0166-2236(94)90156-2 · DOI
  25. Poirier, 1995, Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease, Proc. Natl. Acad. Sci. USA, 92, 12260, 10.1073/pnas.92.26.12260 · DOI
  26. Rudling, 1993, Stimulation of rat hepatic low density lipoprotein receptors by glucagon. Evidence of a novel regulatory mechanism in vivo, J. Clin. Invest., 91, 2796, 10.1172/JCI116522 · DOI
  27. Saito, 1994, Complete cloning and sequencing of rat gp330/“megalin,” a distinctive member of the low density lipoprotein receptor gene family, Proc. Natl. Acad. Sci. USA, 91, 9725, 10.1073/pnas.91.21.9725 · DOI
  28. Sakurai, 1991, cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA, Biochem. Biophys. Res. Commun., 175, 44, 10.1016/S0006-291X(05)81197-0 · DOI
  29. Wang, 1997, Chronic nicotine treatment enhances focal ischemic brain injury and depletes free pool of brain microvascular tissue plasminogen activator in rats, J. Cereb. Blood Flow Metab., 17, 136, 10.1097/00004647-199702000-00002 · DOI
  30. Wang, 1997, Thrombomodulin expression in bovine brain capillaries: Anticoagulant function of the blood-brain barrier, regional differences, and regulatory mechanisms, Arterioscler. Thromb. Vasc. Biol., 17, 19, 10.1161/01.ATV.17.11.3139 · DOI
  31. Watts, 1991, Cell-specific expression of mRNAs encoding Na+,K(+)-ATPase alpha- and beta-subunit isoforms within the rat central nervous system, Proc. Natl. Acad. Sci. USA, 88, 7425, 10.1073/pnas.88.16.7425 · DOI
  32. Willnow, 1992, Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance, J. Biol. Chem., 267, 26172, 10.1016/S0021-9258(18)35732-6 · DOI
  33. Wisniewski, 1997, Biology of A-beta amyloid in Alzheimer's disease, Neurobiol. Dis., 4, 313, 10.1006/nbdi.1997.0147 · DOI · Paper page
  34. Wolf, 1992, Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain, Am. J. Pathol., 141, 37
  35. Wyne, 1996, Expression of the VLDL receptor in endothelial cells, Arterioscler. Thromb. Vasc. Biol., 16, 407, 10.1161/01.ATV.16.3.407 · DOI
  36. Zheng, 1994, Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/α2MR, and the receptor-associated protein (RAP), J. Histochem. Cytochem., 42, 531, 10.1177/42.4.7510321 · DOI
  37. Zlokovic, 1993, Differential expression of Na,K-ATPase alpha and beta subunit isoforms at the blood–brain barrier and the choroid plexus, J. Biol. Chem., 268, 8019, 10.1016/S0021-9258(18)53058-1 · DOI
  38. Zlokovic, 1995, Expression of tissue plasminogen activator in cerebral capillaries: Possible fibrinolytic function of the blood–brain barrier, Neurosurgery, 37, 955, 10.1227/00006123-199511000-00015 · DOI
  39. Zlokovic, 1996, Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood–brain and blood–cerebrospinal fluid barriers, Proc. Natl. Acad. Sci. USA, 93, 4229, 10.1073/pnas.93.9.4229 · DOI · Paper page

Cited by

Sorted by citations

See all 67

Metadata

Authors
Chun, J. T., Wang, L., Pasinetti, G. M., Finch, C. E., & Zlokovic, B. V.
Venue
Experimental Neurology
Publisher
Elsevier BV
Published
1999-05
Volume
157
Issue
1
Pages
194-201
ISSN
0014-4886
DOI
10.1006/exnr.1999.7052
Cited by
67
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review